SCM
ESPR

Symons Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Symons Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,055
Closed -$226K – 74
2021
Q1 		$226K Buy
+8,055
New +$238K 0.12% 74

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Symons Capital Management's ESPR Position: Q2 2021 in Review

Symons Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 8,055 shares — an estimated $226K sold.

Symons Capital Management first reported a position in ESPR in Q1 2021 and held it in 1 quarter. The position peaked at $226K in Q1 2021. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Symons Capital Management reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Symons Capital Management sold 8,055 Esperion Therapeutics shares in Q2 2021, an estimated $226K.
  • Symons Capital Management first reported a position in Esperion Therapeutics in Q1 2021 and held it in 1 quarter.
  • Symons Capital Management's Esperion Therapeutics position peaked at $226K in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Symons Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.